Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-01-07FDA Approved: ABIRATERONE ACETATE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's original application for a generic abiraterone acetate product, expanding access to treatment f…
-
FDA approval · 2018-10-31FDA Approved: ABIRATERONE ACETATE — Original Application (Apotex Corp.)
FDA approved Abiraterone acetate (generic) from Apotex Corp. under an original ANDA, enabling a generic version of the cancer drug for metas…
-
FDA approval · 2018-10-31FDA Approved: ABIRATERONE ACETATE — Original Application (Mylan Pharmaceuticals Inc.)
The FDA approved Mylan's original application for Abiraterone acetate, enabling a generic version of the cancer drug used for metastatic cas…
-
FDA approval · 2018-10-31FDA Approved: ABIRATERONE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc.'s original application for a generic abiraterone acetate product (ABIRATERONE) for the treatment…
-
FDA approval · 2018-05-22FDA Approved: YONSA — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approval of Sun Pharmaceutical Industries' YONSA (abiraterone acetate) under an Original Application for the treatment of prostate cance…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-02-07FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc., indicating an approved update to the pr…
-
FDA approval · 2018-02-02FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for XOFIGO (radium-223 dichloride) by Bayer HealthCare Pharmaceuticals Inc., signaling an expand…
-
FDA approval · 2018-01-09FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for JEVTANA (cabazitaxel) filed by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2017-09-14FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for JEVTANA (cabazitaxel) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2017-07-24FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc.
-
FDA approval · 2016-09-12FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for JEVTANA (cabazitaxel) from Sanofi-Aventis U.S. LLC.
-
FDA approval · 2016-05-17FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) submitted by Janssen Biotech, expanding its labeling.
-
FDA approval · 2016-05-12FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for XOFIGO (radium-223 dichloride) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2016-04-29FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for XOFIGO (radium Ra-223 dichloride) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2016-03-18FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for XOFIGO (radium-223 dichloride) from Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2016-01-22FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for XOFIGO (radium Ra-223 dichloride) from Bayer HealthCare Pharmaceuticals, updating its labeling/i…
-
FDA approval · 2015-11-06FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental NDA for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc., to update the labeling and/or expand an ind…
-
FDA approval · 2015-10-01FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc., reflecting an updated indication/la…
-
FDA approval · 2015-08-05FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc. The approval expands the labelin…
-
FDA approval · 2015-06-18FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA supplemental approval for JEVTANA (cabazitaxel) by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2015-06-11FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves a supplemental application for JEVTANA (cabazitaxel) from Sanofi-Aventis U.S. LLC.
-
FDA approval · 2015-05-12FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for XOFIGO (radium-223 dichloride) from Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2015-03-20FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc.
-
FDA approval · 2015-02-16FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Xofigo (radium-223 dichloride) to expand its approved indication for metastatic castration-resis…
-
FDA approval · 2015-01-20FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc., updating the labeling per the suppl…